Eli Lilly and Company (LLY) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $1134.50 (-0.35%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 13, 2026 | Akash Tewari | Jefferies | $1300.00 | +14.6% |
| Mar 6, 2026 | James Shin | Deutsche Bank | $1285.00 | +13.3% |
| Mar 5, 2026 | Terence Flynn | Morgan Stanley | $1313.00 | +15.7% |
| Feb 24, 2026 | Trung Huynh | RBC Capital | $1250.00 | +10.2% |
| Feb 10, 2026 | Ilya Zubkov | Loop Capital Markets | $1200.00 | +5.8% |
| Feb 5, 2026 | Mohit Bansal | Wells Fargo | $1280.00 | +12.8% |
| Feb 5, 2026 | Evan Seigerman | BMO Capital | $1300.00 | +14.6% |
| Jan 6, 2026 | Michael Yee | UBS | $1250.00 | +10.2% |
| Jan 5, 2026 | David Risinger | Leerink Partners | $1234.00 | +8.8% |
| Dec 16, 2025 | Narumi Nakagiri | Daiwa | $1230.00 | +8.4% |
| Dec 2, 2025 | Evan Seigerman | BMO Capital | $1100.00 | -3.0% |
| Dec 1, 2025 | Tim Anderson | National Bank | $1286.00 | +13.4% |
| Nov 24, 2025 | Terence Flynn | Morgan Stanley | $1290.00 | +13.7% |
| Nov 19, 2025 | Srikripa Devarakonda | Truist Financial | $1182.00 | +4.2% |
| Nov 10, 2025 | Ilya Zubkov | Loop Capital Markets | $950.00 | -16.3% |
| Oct 8, 2025 | Q3 Mounjaro | Guggenheim | $948.00 | -16.4% |
| Aug 17, 2025 | Narumi Nakagiri | Daiwa | $700.00 | -38.3% |
| Aug 13, 2025 | Carter Gould | Cantor Fitzgerald | $825.00 | -27.3% |
| Aug 7, 2025 | Market Perform | Leerink Partners | $715.00 | -37.0% |
| May 2, 2025 | Trung Huynh | UBS | $1050.00 | -7.4% |
Top Analysts Covering LLY
LLY vs Sector & Market
| Metric | LLY | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.08 | 2.25 | 2.42 |
| Analyst Count | 25 | 8 | 18 |
| Target Upside | +18.6% | +16187.2% | +19.5% |
| P/E Ratio | 40.30 | 3.75 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $19.74B | $21.30B | $22.02B | 5 |
| 2026-12-31 | $21.76B | $23.48B | $24.28B | 5 |
| 2027-03-31 | $19.41B | $20.95B | $21.66B | 5 |
| 2027-06-30 | $21.16B | $22.82B | $23.60B | 5 |
| 2027-09-30 | $21.81B | $23.53B | $24.33B | 5 |
| 2027-12-31 | $22.61B | $24.39B | $25.22B | 5 |
| 2028-12-31 | $106.36B | $106.62B | $106.88B | 22 |
| 2029-12-31 | $107.31B | $117.00B | $125.15B | 15 |
| 2030-12-31 | $116.09B | $126.57B | $135.39B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $8.32 | $9.19 | $9.60 | 5 |
| 2026-12-31 | $9.29 | $10.27 | $10.72 | 5 |
| 2027-03-31 | $8.42 | $9.31 | $9.72 | 5 |
| 2027-06-30 | $9.38 | $10.37 | $10.83 | 5 |
| 2027-09-30 | $9.80 | $10.83 | $11.31 | 5 |
| 2027-12-31 | $6.42 | $7.10 | $7.41 | 5 |
| 2028-12-31 | $43.23 | $49.14 | $56.41 | 10 |
| 2029-12-31 | $49.31 | $55.27 | $60.27 | 4 |
| 2030-12-31 | $54.41 | $60.97 | $66.50 | 4 |
Frequently Asked Questions
What is the analyst consensus for LLY?
The consensus among 25 analysts covering Eli Lilly and Company (LLY) is Buy with an average price target of $1324.67.
What is the highest price target for LLY?
The highest price target for LLY is $1313.00, set by Terence Flynn at Morgan Stanley on 2026-03-05.
What is the lowest price target for LLY?
The lowest price target for LLY is $236.00, set by Chris Shibutani at Goldman Sachs on 2021-12-17.
How many analysts cover LLY?
25 analysts have issued ratings for Eli Lilly and Company in the past 12 months.
Is LLY a buy or sell right now?
Based on 25 analyst ratings, LLY has a consensus rating of Buy (2.08/5) with a +18.6% upside to the consensus target of $1324.67.
What are the earnings estimates for LLY?
Analysts estimate LLY will report EPS of $9.19 for the period ending 2026-09-30, with revenue estimated at $21.30B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.